Repeat testing for autoantibodies that signal more severe disease in rheumatoid arthritis patients that are seronegative for the biomarkers after treat to target therapy is started is neither helpful or cost effective, say Australian rheumatologists. That’s because patients who are double negative for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) are highly unlikely to ...
Serial ACPA measures unnecessary in seronegative RA patients
By Sunalie Silva
22 Jul 2020